Wedbush Research Analysts Reduce Earnings Estimates for SWTX

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Equities researchers at Wedbush reduced their FY2027 earnings per share (EPS) estimates for shares of SpringWorks Therapeutics in a research note issued on Monday, January 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $3.42 for the year, down from their previous estimate of $3.47. Wedbush has a "Outperform" rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics' current full-year earnings is ($3.12) per share.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.03. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The business had revenue of $49.10 million during the quarter, compared to analyst estimates of $53.28 million. During the same period last year, the firm posted ($1.27) EPS. The company's revenue was up 4810.0% on a year-over-year basis.

A number of other research analysts have also weighed in on SWTX. HC Wainwright cut their price objective on SpringWorks Therapeutics from $76.00 to $74.00 and set a "buy" rating for the company in a research report on Tuesday, November 12th. Evercore ISI started coverage on SpringWorks Therapeutics in a research note on Wednesday, November 20th. They set an "outperform" rating and a $60.00 price target for the company. Finally, Guggenheim reduced their price objective on SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $70.00.

SpringWorks Therapeutics Stock Up 3.0 %

NASDAQ SWTX traded up $0.98 on Wednesday, reaching $33.48. The company had a trading volume of 1,753,718 shares, compared to its average volume of 2,302,897. The stock has a market capitalization of $2.49 billion, a PE ratio of -8.63 and a beta of 0.82. SpringWorks Therapeutics has a 12 month low of $28.21 and a 12 month high of $53.92. The firm's 50 day moving average price is $37.97 and its 200 day moving average price is $36.40.

Institutional Trading of SpringWorks Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alpha DNA Investment Management LLC purchased a new position in shares of SpringWorks Therapeutics during the third quarter valued at approximately $411,000. D. E. Shaw & Co. Inc. lifted its stake in shares of SpringWorks Therapeutics by 16.9% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 758,712 shares of the company's stock worth $28,581,000 after acquiring an additional 109,865 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in SpringWorks Therapeutics during the 3rd quarter valued at $7,296,000. Los Angeles Capital Management LLC grew its position in SpringWorks Therapeutics by 238.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 47,212 shares of the company's stock valued at $1,513,000 after acquiring an additional 33,255 shares during the last quarter. Finally, Seven Eight Capital LP purchased a new stake in SpringWorks Therapeutics in the second quarter worth $1,854,000.

Insider Transactions at SpringWorks Therapeutics

In other news, COO Badreddin Edris sold 20,000 shares of the firm's stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $41.97, for a total value of $839,400.00. Following the completion of the sale, the chief operating officer now owns 209,600 shares in the company, valued at approximately $8,796,912. This trade represents a 8.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.61% of the company's stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.